Contraception

Clinical Gynecology

Volumn , Issue , 2006, Pages 831-842

  Burkman, Ronald T ^a,b   Dardano, Kristin L ^a,b   Bailey Sarnelli, Patricia E ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c BAYSTATE HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68149173500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06691-7.50063-7     Document Type: Chapter

References (32)

1. Henshaw SK Unintended pregnancy in the United States. Fam Plann Perspect 1998, 30:24-29. (III, B).
2. Piccinino LJ, Mosher WD Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998, 30:4-10. (III, B).
3. Dardano KL, Burkman RT Contraceptive compliance. Obstet Gynecol Clin North Am 2000, 27:933-941. (IIa, B).
4. Gilliam ML, Derman RJ Barrier methods of contraception. Obstet Gynecol Clin North Am 2000, 27:841-858. (IIa, B).
5. Trussell J, Vaughan B Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999, 31:64-72. (III, B).
6. Raymond EG, Chen PL, Luoto J Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial. Obstet Gynecol 2004, 103:430-439. (Ib, A).
7. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998, 339:504-510. (Ib, A).
8. Dardano KL, Burkman RT The intrauterine contraceptive device: an often-forgotten and maligned method of contraception. Am J Obstet Gynecol 1999, 181:1-5. (IIa, B).
9. Backman T, Rauramo I, Huhtala S, Koskenvuo M Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004, 190:50-54. (III, B).
10. Marjoribanks J, Lethaby A, Farquhar C Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2003, CD003855. (Ib, A).
11. Anderson FD, Hait H A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003, 68:89-96. (Ib, A).
12. Potter L, Oakley D, de Leon-Wong E, Canamar R Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996, 28:154-158. (III, B).
13. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992, 80:708-714. (IIb, B).
14. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?. J Soc Gynecol Investig 1998, 5:271-276. (IIb, B).
15. Schlesselman JJ Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997, 12:1851-1863. (IIa, B).
16. Ness RB, Soper DE, Holley RL, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation And Clinical Health (PEACH) study. Am J Obstet Gynecol 2001, 185:121-127. (III, B).
17. Davis A, Lippman J, Godwin A, et al. Triphasic norgestimate/ethinyl estradiol oral contraceptive for the treatment of dysfunctional uterine bleeding. Obstet Gynecol 2000, 96:913-920. (Ib, A).
18. Michaelsson K, Baron JA, Farahmand BY, et al. Oral contraceptive use and risk of hip fracture: a case-control study. Lancet 1999, 353:1481-1484. (IIa, B).
19. Spector TD, Hochberg MC The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 1990, 43:1221-1230. (IIa, B).
20. Burkman RT Cardiovascular issues with oral contraceptives: evidenced-based medicine. Int J Fertil Womens Med 2000, 45:166-174. (IIa, B).
21. Winkler UH Blood coagulation and oral contraceptives. A critical review. Contraception 1998, 57:203-209. (IV, C).
22. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996, 347:1713-1727. (IIa, B).
23. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002, 346:2025-2032. (IIa, B).
24. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive: a randomized controlled trial. JAMA 2001, 285:2347-2354. (Ib, A).
25. Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002, 77:S19-S26. (Ia, A).
26. Archer DF, Bigrigg A, Smallwood GH, et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002, 77:S27-S31. (Ia, A).
27. Timmer CJ, Mulders TM Pharmacokinetics of etonogestrel and ethinyl estradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000, 39:233-242. (III, B).
28. Roumen FJ, Apter D, Mulders TM, Dieben TO Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001, 16:469-475. (III, B).
29. Kaunitz AM Current concepts regarding use of DMPA. J Reprod Med 2002, 47:785-789. (IIa, B).
30. Pelkman C Hormones and weight change. J Reprod Med 2002, 47:791-794. (IIb, B).
31. Meckstroth KR, Darney PD Implant contraception. Semin Reprod Med 2001, 19:339-354. (IIb, B).
32. Westhoff C Clinical practice. Emergency contraception. N Engl J Med 2003, 349:1830-1835. (IIa, B).